Industry and academic leaders will describe how small immune cell subsets shape the human immune response.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

Tumors’ mutations can encode the seeds of their own destruction, in the form of immunogenic peptides recognized by T cells.

Neoantigens may serve as valuable targets for new immunotherapies.

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.

Billionaire Silicon Valley entrepreneur Sean Parker donates $250 million to unite the cancer research community around the common goal of developing new immunotherapies.

Understanding cancer’s relationship with the human microbiome could transform immune-modulating therapies.